| scholarly article | Q13442814 |
| P2093 | author name string | Olav Dalgard | |
| Eva Skovlund | |||
| Jon Florholmen | |||
| Mona Holberg-Petersen | |||
| Kristian Bjøro | |||
| Olle Reichard | |||
| Hans Verbaan | |||
| Bjørn Myrvang | |||
| Helmer Ring-Larsen | |||
| Einar Bjornsson | |||
| Ståle Ritland | |||
| Aril Frydén | |||
| Bo Sundelöf | |||
| Kjell Hellum | |||
| North-C Group | |||
| P2860 | cites work | Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy | Q27860724 |
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. | Q41604120 | ||
| Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy | Q42725944 | ||
| Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study | Q42989003 | ||
| Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. | Q42993387 | ||
| Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. | Q43046858 | ||
| Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study | Q44038693 | ||
| A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. | Q44527614 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| virology | Q7215 | ||
| ribavirin | Q421862 | ||
| Hepatitis C virus | Q708693 | ||
| interferon alfa | Q6046441 | ||
| pegylated interferon | Q7160835 | ||
| P304 | page(s) | 35-42 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response | |
| P478 | volume | 47 |
| Q58788714 | 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C |
| Q35962849 | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. |
| Q37356788 | A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan |
| Q38552131 | APASL consensus statements and management algorithms for hepatitis C virus infection. |
| Q42400012 | APASL consensus statements and recommendation on treatment of hepatitis C. |
| Q42997291 | Antiviral treatment of chronic hepatitis C in clinical routine |
| Q50568678 | Chronic hepatitis C genotype 2 or 3 short treatment. |
| Q37823576 | Current therapies for chronic hepatitis C. |
| Q42983809 | Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection |
| Q43048116 | Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection |
| Q33938574 | Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study |
| Q42992774 | Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis |
| Q34342092 | Evolution of interferon-based therapy for chronic hepatitis C. |
| Q27489903 | Expert opinion on the treatment of patients with chronic hepatitis C |
| Q35607835 | Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach |
| Q27490396 | Four-week pegylated interferon a-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study |
| Q36277992 | Glucose abnormalities in Asian patients with chronic hepatitis C |
| Q35259824 | HBV and HCV therapy. |
| Q41703740 | HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984. |
| Q45362982 | Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy |
| Q56932766 | Hepatitis C (chronic) |
| Q42997280 | Hepatitis C treatment response kinetics and impact of baseline predictors |
| Q43034871 | IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection |
| Q42995130 | Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin |
| Q38224436 | Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview |
| Q36765588 | Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study |
| Q47566260 | Increased hope following successful treatment for hepatitis C infection |
| Q37654502 | Individualization of chronic hepatitis C treatment according to the host characteristics |
| Q42382462 | Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. |
| Q37805772 | Individualizing treatment duration in hepatitis C virus genotype 2/3‐infected patients |
| Q37288393 | Interferon-based therapy for chronic hepatitis C: current and future perspectives |
| Q38174868 | Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients |
| Q38134774 | Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. |
| Q24644729 | Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3? |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q51836024 | KASL clinical practice guidelines: management of hepatitis C. |
| Q42988913 | Management of patients with hepatitis C virus genotype 2 or 3: comments on updated American Association for the Study of Liver Diseases practice guidelines |
| Q37316248 | Managing pediatric hepatitis C: current and emerging treatment options |
| Q34334776 | Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. |
| Q40747582 | New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial). |
| Q40108841 | Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response |
| Q38295810 | Optimal therapy of genotype-2 chronic hepatitis C: what's new? |
| Q42984893 | Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin |
| Q33855483 | Optimizing the dose and duration of therapy for chronic hepatitis C. |
| Q37636095 | Optimizing the treatment of chronic viral hepatitis C. |
| Q34521371 | Peginterferon and ribavirin treatment for hepatitis C virus infection |
| Q42978688 | Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2. |
| Q34409039 | Predicting the probable outcome of treatment in HCV patients |
| Q28543090 | Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3 |
| Q88881128 | Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection |
| Q42981176 | Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure |
| Q43037030 | Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. |
| Q37972765 | Response-guided and -unguided treatment of chronic hepatitis C. |
| Q39739238 | Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future |
| Q50552503 | Response-guided peginterferon-alpha-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads. |
| Q45359763 | Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. |
| Q42980225 | Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study |
| Q26864571 | Review article: HCV genotype 3 – the new treatment challenge |
| Q37019765 | SASLT practice guidelines: management of hepatitis C virus infection. |
| Q37846232 | Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future |
| Q48044503 | Scandinavian Journal of Gastroenterology - the editors-in-chief |
| Q42980371 | Short treatment to patients with genotype 2 or 3. |
| Q27491047 | Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial |
| Q35164100 | Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. |
| Q42979298 | Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR. |
| Q36140466 | Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. |
| Q45365640 | Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance |
| Q42987104 | Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients |
| Q27489040 | The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy |
| Q35759214 | The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection |
| Q35658214 | Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. |
| Q42232204 | Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve 'real-life' patients in India. |
| Q38164262 | Treatment of genotype 2 and genotype 3 hepatitis C virus (HCV) infection in human immunodeficiency virus positive patients |
| Q38002889 | Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations |
| Q34323192 | Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA |
| Q37960400 | Treatment of non-genotype 1 hepatitis C virus patients. |
| Q42984815 | Treatment of patients infected with chronic hepatitis C genotype 2 and 3: more data, more questions? |
| Q27000806 | Update on the treatment of patients with non-genotype 1 hepatitis C virus infection |
| Q42980363 | Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection |
| Q37972773 | What's new in HCV genotype 2 treatment |
| Q81441708 | [Diagnostics and therapy of chronic hepatitis B and C] |
Search more.